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Cancer is likely to affect up to one in
three people in the developed world
over their lifetimes but, in spite of
impressive advances in
understanding the molecular basis of
cancer over recent years, leukaemia
researcher Mel Greaves believes
there is still widespread public
misunderstanding about the disease.
He has set out to counter that in a
popular book* about the disease and
believes a Darwinian, evolutionary
approach is the best way to help a
confused public and the patient who
wonders ‘Why me?’.
An evolutionary approach to
aspects of the human condition has
become fashionable in recent years.
Randolph Nesse and George
Williams coined the term ‘Darwinian
medicine’ as a way of looking at how
we get sick, and the approach of
studying how our evolutionary past
may throw light on current issues has
been taken up enthusiastically in
many fields.
We now know from advances in
molecular genetics of the past
25 years that cancer develops as a
chromosomal gene disorder in single
cells. But it is different and more
complex than the 5,000 or so other
human genetic diseases that arise as
inherited, single-gene traits. It is also
different from the disease pattern
the public most readily grasps of
common infectious illnesses, caused
by individual culprit micro-
organisms that are, on the whole,
amenable to treatment or
prevention. The simple formula,
infection with X = disease Y: treat
with Z is not applicable to cancer
and is part of the cause for confusion
and distress.
To begin to tackle this confusion,
Greaves, head of the Leukaemia
Research Fund Centre for Cell and
Molecular Biology at the Institute of
Cancer Research in London, starts
with some history. Cancer is old. The
prize for oldest identified tumour
currently rests with a haemangioma
(a benign tumour of blood vessels)
and an uncertain cancer type whose
unique imprints were identified in
dinosaur bones from the Jurassic
period, more than 150 million years
ago. But more importantly, cancer
appears intimately tied up with the
development of multicellular
organisms. “It reflects such an
intrinsic feature of multicellular
creatures that we can be reasonably
confident that benign and malignant
growths have been around for half a
billion years or so,” says Greaves.
“Understanding the causal
mechanisms involved and the real
why and how it happens is only
possible with some biological
archaeology — digging out what
makes us tick, the deep legacies
inherent in our design, and the
pitfalls that can open the door to
cancer.” Again in contrast to the
popular conception of infectious
diseases, Greaves argues that in a
sense every patient’s cancer is
unique. “In so far as it is a disease, it
is a collection of very many (a
thousand or so) disorders of cell and
Evolutionary rift: An immunofluorescence
light micrograph of prostate cancer cells. This
is one of the common cancers that may result
from a rift between our ancient evolutionary
legacy and current lifestyles.
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tissue function that have one special
biological property in common — the
territorial expansion of a mutant
clone.” The evolutionary approach,
however, may not only illuminate
how cancer might have emerged as a
fundamental consequence of
multicellular organisms but also
throw light on how a single mutant
cell might develop a clone that
results in cancer.
At the heart of Greaves’ account
is how the evolutionary view flags up
the conflict between modern human
behaviour and our genetic
inheritance.
“Homo sapiens occupy a special
and unenviable place in the scheme
of things. Superimposed on our very
ancient genetic memories is a more
recent, million-year-old evolutionary
legacy that we acquired or modified
as an emerging species of hominid
primates,” says Greaves. But it is a
flawed inheritance as far as cancer is
concerned. “Flawed by a double
whammy from what were, originally,
very advantageous adaptations. First,
our ability to survive long after our
natural reproductive period. Second,
our propensity to interfere both with
our own and other people’s biology.
Examples include our persistent
pursuit of pleasure in the form of
smoking, sunshine and sex and,
rather less transparently, our adoption
of diets, physical inactivity, and
reproductive patterns that are at odds
with our inherent biology” he says.
The undesirable biological
consequences are slow, chronic and
stealth-like, impacting mostly after
our normal reproductive period.
They escape the filter of natural
selection and conspire together to
both outflank and exploit the efficacy
of otherwise very resilient biological
controls.
“We have become social beasts
out of synch with our genetics,
caught in a nature–nurture mismatch,
our pedestrian genetics too slow to
catch up with or adapt to our strident
and exotic social habits. The
consequence is accumulative damage
and a potent ratcheting-up of risk for
the emergence of cancer in an ageing
and puzzled body,” he says.
The molecular evidence of a
progression of cells towards a
cancerous state suggests that certain
cell types may be more vulnerable.
Cells with extensive longevity,
replicative potential and migratory
capacity should be most at risk of
cancerous transformation. The cells
concerned exist transiently in the
developing embryo and foetus and,
throughout life, in those tissues that
are continually self-renewing, that
proliferate on demand, or that can
regenerate after injury (blood, skin,
the linings of the lung, intestines, the
endocrine glands, and liver). This
prediction is amply fulfilled by the
evidence of cancer types we have.
Superimposed on our very
ancient genetic memories is a
more recent milllion-year-old
evolutionary legacy
It may be that we are under constant
threat from potentially cancerous
cells. “Most ageing men (say,
70 years plus) have a locally invasive
carcinoma in the prostate gland as
revealed by autopsy studies on
prostate glands in individuals who
died of non-malignant causes,” says
Greaves. “Similarly for breast cancer.
The lifetime risk of carcinoma in situ
(CIS) — a halfway house in cancer
development — in the breast may be
as high as one in four. In one so far
unconfirmed Danish study of
biopsies from medico-legal autopsies,
one third of all women in their 40s
had CIS. None were found in a small
sample of women in their 20s.”
The evolutionary perspective on
cancer is initially depressing for
patients. For a clone to succeed in
establishing cancer suggests that it is
robust and that any treatment is
likely to leave a few cells unscathed
which is all that is needed for the
cancer to progress. Clearly, the odds
are really stacked up against
therapeutic success as the cancer
clone evolves and expands. “It really
is no surprise at all then, now we see
more clearly the genetic and
evolutionary game plan of cancer
cells, that chemotherapy for
metastatic disease most often fails as
some mutant cells, insulated from
the insult, escape through the most
stringent of bottlenecks,” says
Greaves.
The reality, he says, is that
treatment for cancer can be nasty and
toxic, and doctors and scientists have
overall done a rather poor job in
explaining why this is so and what
the underlying problems are. “And
yet, there have been real
improvements in clinical
management, a revolution in our
understanding of the underlying
biology of cancer, and a much more
sophisticated appreciation of the
multiple factors involved in
causation. At last we have some
understanding what it really is, why
the complexity exists.”
And there is optimism arising
from this evolutionary perspective. It
flags up the potential to improve
prevention of the disease and
although it is unlikely that there will
be any single, blanket treatments
against cancer, there are aspects
tumours have in common, such as
developing a blood supply, that may
provide a route in to tackling a range
of tumours. “There still will not be a
‘magic bullet’, however
sophisticated, for cancer in general,”
he argues. “Political leaders and
advisers should now recognize that
the problem isn’t equivalent to the
task of building the first atom bomb
and getting man on the moon. The
intricacies of millions of years of
evolutionary biology are involved,
richly embroidered and coupled in
conflict with human diversity and
behaviour.”
*Cancer: The Evolutionary Legacy by Mel
Greaves. Oxford University Press, Oxford
OX2 6DP, UK.
